Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Love Pharma Inc.
(CSE:
LUV
)
N/A
UNCHANGED
Last Price
Updated: 1:45 PM EDT, May 25, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
0.0100 (250,000)
Ask (Size)
0.0650 (2,000)
Prev. Close
0.0150
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Jolt Health To Acquire HCQ Transdermal Patch Technology
May 06, 2024
Via
ACCESSWIRE
Love Pharma Inc. Announces Share Consolidation
February 27, 2023
Via
ACCESSWIRE
Performance
More News
Read More
Love Pharma Sells Microdoz, Increases Focus on Biotechnology
December 14, 2022
Via
ACCESSWIRE
Acquisition Has Love Pharma’s Naltrexone on NIH Shortlist to Address Unmet Medical Need—Treatment for Long Covid
November 03, 2022
From
Love Pharma Inc.
Via
GlobeNewswire
Love Pharma Investee, Starton Therapeutics, Strengthens Board With New Member (Re-release)
November 02, 2022
Via
ACCESSWIRE
Naltrexone Demonstrates Promising Long COVID Application
October 20, 2022
Via
ACCESSWIRE
Love Pharma Closes Acquisition of Doc Hygiene
October 19, 2022
Via
ACCESSWIRE
Love Pharma - Johns Hopkins University Psilocybin Trial Advances Toward Launch in 2022
October 13, 2022
Via
ACCESSWIRE
Love Pharma Signs Letter of Intent To Acquire Naltrexone Therapeutics Inc.
October 11, 2022
Via
ACCESSWIRE
Love Pharma Subsidiary Doc Hygiene Delivers Sanitizer Products To Support Community Needs With Operation "Clean Hands" and Closes Final Tranche of Financing
September 30, 2022
Via
ACCESSWIRE
Love Pharma Launches Proprietary E-Commerce Platform for Online Sales
September 21, 2022
Via
ACCESSWIRE
Love Pharma Initiates First Steps Towards a Strategic Alliance with Starton Therapeutics with Investment in this Biotech Leader
September 07, 2022
Via
ACCESSWIRE
Love Pharma Delivers Letter to Shareholders
August 25, 2022
Via
ACCESSWIRE
Love Pharma Inc. Announces First Closing of Financing
August 24, 2022
Via
ACCESSWIRE
Love Pharma Announces Strategic Acquisition of Doc Hygiene Pharmaceuticals Inc.
August 16, 2022
Via
ACCESSWIRE
Love Pharma Inc. Announces Second Closing of Financing
June 29, 2022
From
Love Pharma Inc.
Via
AccessWire
Love Pharma Inc. Announces Closing of Financing
May 06, 2022
From
Love Pharma Inc.
Via
AccessWire
Love Pharma Inc. Announces First Closing of Financing
April 05, 2022
From
Love Pharma Inc.
Via
AccessWire
Love Pharma Updates Microdoz Proposed Acquisition with Global Leader in Psychedelic Research
March 03, 2022
From
Love Pharma Inc.
Via
AccessWire
Topics
Cannabis
Intellectual Property
Exposures
Cannabis
Intellectual Property
Love Pharma Signs Letter of Intent to Acquire 100% Interest in MicrDoz Therapy Inc. To Expedite Pilot Study of Psilocybin Assisted Treatment of Cannabis Use Disorder with World Leading University
November 23, 2021
From
Love Pharma Inc.
Via
AccessWire
Topics
Cannabis
Intellectual Property
Exposures
COVID-19
Cannabis
Intellectual Property
LOVE Pharma Announces Advanced Psilocybin Delivery System
October 20, 2021
From
Love Pharma Inc.
Via
AccessWire
Exposures
Product Safety
Love Pharma Inc., Announces Listing on Frankfurt Stock Exchange
October 12, 2021
From
Love Pharma Inc.
Via
AccessWire
LOVE Pharma Names Joshua Maurice Chief Operating Officer
October 06, 2021
From
Love Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Love Pharma, Inc., Formerly Glenbriar Technologies, Inc., Announces Name Change, Consolidation, and Acquisition of Kick Pharmaceuticals, Inc
September 30, 2021
From
Love Pharma Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.